The U.S. Department of Defense has recently awarded the following notable contracts related to the field of chemical, biological, radiological and nuclear (CBRN) equipment or life science research of interest for potential applications in biodefense:
GlaxoSmithKline, Research Triangle Park, North Carolina, has been awarded a maximum $11,775,022 firm-fixed-price, indefinite-quantity contract for influenza vaccine and prefilled syringes.
BioCSL, King of Prussia, Pennsylvania, has been awarded a maximum $10,233,601 firm-fixed-price, indefinite-quantity contract for influenza vaccine and prefilled syringes.
Each award is for a one-year base contract with no option periods and with a June 14, 2016, performance completion date.
Using services are Army, Navy, Air Force, Marine Corps and federal civilian agencies. Type of appropriation is fiscal 2015 through fiscal 2016 defense working capital funds. The contracting activity is the Defense Logistics Agency Troop Support, Philadelphia, Pennsylvania (SPE2DP-15-D-0004).
